Navigation Links
Development of new anti-cancer gene therapy approach using lentiviral vectors
Date:3/29/2010

Neuherberg, March 29, 2010. Helmholtz Zentrum Mnchen has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

The future of gene therapy approaches in cancer treatment is especially dependent on the quality of the vectors involved in the regulation of gene expression in the tumor cells. Lentiviruses are a very promising vector system for this they even reach difficult-to-access cell types such as the hematopoietic cells of the blood-forming system.

With their new research cooperation Helmholtz Zentrum Mnchen and SIRION BIOTECH seek to optimize the use of lentiviruses as gene vectors for hematopoietic cells. Over the long term this may result in an important step forward in the therapy of malignant lymphomas. The Federal Ministry for Economics and Technology is funding the project over the next two years with approximately 500,000 euros.

"We quite consciously decided on a cooperation partner from the biotech sector," said Professor Gnther Wess, scientific-technical director of Helmholtz Zentrum Mnchen. "The symbiosis of our scientific expertise in the field of lentiviruses with the technical know-how of SIRION BIOTECH promises to yield valuable insights about the molecular disease mechanisms and the function of disease-relevant genes in the blood cells."

Dr. Nataa Anastasov, who is in charge of the project at the Institute of Radiation Biology of Helmholtz Zentrum Mnchen, and her colleagues from SIRION BIOTECH already have concrete ideas regarding the new generation of lentiviruses: "We want to specifically refine the lentiviral vectors to target the tumor cell markers." To achieve this, the researchers first want to develop new cell lines in the laboratory with improved binding characteristics for virus production.

"We are very pleased that Helmholtz Zentrum Mnchen has chosen to cooperate with our company due to our specialization in genetically modified cells and viral vector technologies," said Dr. Jrgen Flach, CEO of SIRION BIOTECH. Both cooperation partners are confident that over the long term they can make an important contribution to the treatment of lymphomas.


'/>"/>

Contact: Sven Winkler
presse@helmholtz-muenchen.de
49-898-931-873-946
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. Compound screening for drug development made simpler
2. Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments comprehensive, low cost fingerprint development kit
3. Chemists influence stem-cell development with geometry
4. Opposing functions of a key molecule in the development of organisms
5. Development of more muscular trout could boost commercial aquaculture
6. Sonic hedgehog gene found in an unexpected place during limb development
7. Model may offer better understanding of embryonic development
8. Chemical competition: Research identifies new mechanism regulating embryonic development
9. ACS webinar features developments in online water and wastewater monitoring
10. Rondaxe and TD2 form strategic drug development alliance
11. Zebrafish swim into drug development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: